The Ministry of Health, Labor and Welfare issued a pharmaceutical safety information bulletin on December 1, notifying physicians that interstitial pneumonia has been added to the list of clinically significant adverse drug reactions (ADRs) in the package inserts for the…
To read the full story
Related Article
- Add Interstitial Pneumonia to Daklinza, Sunvepra Labels: MHLW
October 21, 2015
- PMDA Reviewing Daklinza, Sunvepra for Risk of Interstitial Pneumonia
September 28, 2015
REGULATORY
- Unami Tapped as Japan’s New Top Finance Bureaucrat
August 3, 2026
- MHLW Names Uchiyama New Pharma Bureau Chief in Senior Shakeup
August 3, 2026
- Japan to Ease Olanzapine Diabetes Contraindication for Antiemetic Use
July 31, 2026
- Pipe Damage Causes Water Leak at Sawai Plant after Quake: MHLW
July 30, 2026
- MHLW Urges Stable Supply of Drugs after Kumamoto Earthquake
July 30, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





